

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

ASTRAZENECA LP, ASTRAZENECA AB,
ASTRAZENECA UK LIMITED, and
ASTRAZENECA PHARMACEUTICALS LP,

Plaintiffs,

V.

PRINCETON PHARMACEUTICAL INC.,

Defendant.

Civil Action No. _____

**SUPPLEMENTAL INFORMATION FOR PATENT CASES
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs hereby provide the information below with respect to the deadlines set forth in 21 U.S.C. § 355(j):

Date Patentee(s) Received Notice: No earlier than October 3, 2015

Date of Expiration of Patent: 6,251,910 (July 15, 2018)
6,525,060 (December 2, 2019)
7,250,419 (December 2, 2019)
7,265,124 (July 9, 2021)
8,425,934 (April 17, 2030)

Thirty Month Stay Deadline¹ No earlier than January 20, 2019

¹ The stay preventing approval of the proposed generic products expires no earlier than January 20, 2019 (seven and one-half years from the new chemical entity approval on July 20, 2011). *See* 21 U.S.C. § 355(j)(5)(F)(ii).

DATED: November 16, 2015

MCCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Michael P. Kelly (#2295)

Daniel M. Silver (#4758)

Benjamin A. Smyth (#5528)

Renaissance Centre

405 N. King Street, 8th Floor

Wilmington, Delaware 19801

(302) 984-6300

mkelly@mccarter.com

dsilver@mccarter.com

bsmyth@mccarter.com

*Attorneys for Plaintiffs AstraZeneca AB,
AstraZeneca Pharmaceuticals LP,
AstraZeneca LP, and AstraZeneca UK Limited*

OF COUNSEL:

Charles E. Lipsey

Ryan P. O'Quinn

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

11955 Freedom Drive

Reston, VA 20190

(571) 203-2700

Charles.Lipsey@finnegan.com

Ryan.O'Quinn@finnegan.com

Mark J. Feldstein

Jill K. MacAlpine

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

901 New York Ave., N.W.

Washington, D.C. 20001

(202) 408-4000

Mark.Feldstein@finnegan.com

Jill.MacAlpine@finnegan.com